Pharmstandard Ventures

Profile

Pharmstandard Ventures is a venture capital firm based in Russia, operating as the venture arm of Pharmstandard, JSC, a leading pharmaceutical company. Founded in 2013 originally as Inbio Ventures, the firm rebranded as Pharmstandard Ventures after a corporate restructuring in 2017. The team comprises professionals with extensive experience in the academic and biopharmaceutical sectors, as well as venture investments, focusing on breakthrough drug development projects globally.

The firm specializes in innovative drug discovery and development projects targeting unmet medical needs. Its investments focus on therapeutic areas such as oncology, inflammation, ophthalmology, autoimmune diseases, orphan genetic diseases, metabolic disorders, fibrotic diseases, and cell-based therapy. Pharmstandard Ventures partners with national market leaders like Pharmstandard and Generium for licensing and co-development opportunities in the Russian/CIS markets.

Notable portfolio companies of Pharmstandard Ventures include Jounce Therapeutics, which is focused on cancer treatment, Neon Therapeutics, specializing in immune system therapies for cancer, and Protagonist Therapeutics, which develops targeted oral peptide therapies for inflammatory bowel diseases. Other significant investments are Avelas Biosciences, a developer of platform technology for cell-penetrating peptides, and TearSolutions, Inc., in the realm of ophthalmological treatments.